The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer
Authors:
- Stefanie AustSAStefanie Aust
- Peter HorakPHPeter Horak
- Dietmar PilsDietmar Pils
- Sophie PilsSPSophie Pils
- Christoph GrimmChristoph Grimm
- Reinhard HorvatRHReinhard Horvat
- Dan TongDTDan Tong
- Bernd SchmidBSBernd Schmid
- Paul SpeiserPSPaul Speiser
- Alexander ReinthallerARAlexander Reinthaller
- Stephan PolterauerStephan Polterauer
Open Access
- 14 March 2013
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 115
Abstract
Background: Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), a coregulator of the estrogen receptors (ERs) alpha and beta, is a potential proto-oncogene in hormone dependent gynecological malignancies. To better understand the role of PELP1 in epithelial ovarian cancer (EOC), the protein expression and prognostic significance of PELP1 was evaluated together with ERalpha and ERbeta in EOC tissues. Methods: The expression of PELP1, ERalpha, and ERbeta was characterized in tumor tissues of 63 EOC patients. The prognostic value was calculated performing log-rank tests and multivariate Cox-Regression analysis. In a second step, validation analysis in an independent set of 86 serous EOC patients was performed. Results: Nuclear PELP1 expression was present in 76.2% of the samples. Prevalence of PELP1 expression in mucinous tumors was significantly lower (37.5%) compared to serous (85.7%) and endometrioid tumors (86.7%). A significant association between PELP1 expression and nuclear ERbeta staining was found (p=0.01). Positive PELP1 expression was associated with better disease-free survival (DFS) (p=0.004) and overall survival (OS) (p=0.04). The combined expression of ERbeta+/PELP1+ revealed an independent association with better DFS (HR 0.3 [0.1-0.7], p=0.004) and OS (HR 0.3 [0.1-0.7], p=0.005). In the validation set, the combined expression of ERbeta+/PELP1+ was not associated with DFS (HR 0.7 [0.4-1.3], p=0.3) and OS (HR 0.7 [0.3-1.4], p=0.3). Conclusion: Positive immunohistochemical staining for the ER coregulator PELP1, alone and in combination with ERbeta, might be of prognostic relevance in EOC.Keywords
This publication has 30 references indexed in Scilit:
- Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancerBreast Cancer Research, 2012
- Regulation of rDNA Transcription by Proto-Oncogene PELP1PLOS ONE, 2011
- Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall SurvivalPathology and Oncology Research, 2011
- Extranuclear Functions of ER Impact Invasive Migration and Metastasis by Breast Cancer CellsCancer Research, 2010
- PELP1: A novel therapeutic target for hormonal cancersIUBMB Life, 2010
- Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumorsGynecologic Oncology, 2009
- Ovarian CancerAnnual Review of Pathology: Mechanisms of Disease, 2009
- Oncogenic Potential of the Nuclear Receptor Coregulator Proline-, Glutamic Acid–, Leucine-Rich Protein 1/Modulator of the Nongenomic Actions of the Estrogen ReceptorCancer Research, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Functional and biological properties of the nuclear receptor coregulator PELP1/MNARNuclear Receptor Signaling, 2007